Fig. 3
From: Neuropathology of RAN translation proteins in fragile X-associated tremor/ataxia syndrome
Validation of new FMRpolyG antibodies on FXTAS brain tissue. a Western blot using GFP and CTF1 with and without blocking peptide in HEK293 cells that were either mock transfected (lanes1) or transfected with EGFP-N1 plasmid (lanes 2), FMRpolyG 100GFP (lanes 3) and ATG FMRpolyG99GFP (lanes 4). Tubulin used as loading control. b Representative brain images from FXTAS patients stained using CTF1 antibody with and without blocking peptide at 4x (top), 20x (middle) and 60x (bottom) magnification. Nuclei stained with hematoxylin. Scale bars are 500 μm, 100 μm and 20 μm respectively. c Staining of control and FXTAS brain tissue using pre-bleed serum from CTF1 antibody production. Nuclei stained with hematoxylin. Scale bar = 20 μm. d Western blot using GFP and NTF1 with and without blocking peptide in HEK293 cells that were either mock transfected (lanes1) or transfected with EGFP-N1 plasmid (lanes 2) and FMRpolyG100GFP (lanes 3). Tubulin used as loading control. e Representative brain images from FXTAS patients stained using NTF1 antibody with and without blocking peptide at 4x (top), 20x (middle) and 60x (bottom) magnification. Nuclei stained with hematoxylin. Scale bars are 500 μm, 100 μm and 20 μm respectively. f Staining of control and FXTAS brain tissue using pre-bleed serum from NTF1 antibody production. Nuclei stained with hematoxylin. Scale bar = 20 μm